Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don’t respond to immunotherapy.